JMP Securities analyst Silvan Tuerkcan downgraded Intellia Therapeutics to Market Perform from Outperform without a price target. The analyst views the shares as fairly valued at current levels. Moving in-vivo editing to the U.S. will represent a major milestone, but there is little upside for the stock with more downside risk as the company engages regulators, Tuerkcan tells investors in a research note. The analyst says 2023 will bring little in terms of clinical updates for Intellia with the focus on regulatory interactions.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NTLA:
- Intellia Therapeutics downgraded to Market Perform from Outperform at JMP Securities
- Intellia awarded innovation passport in UK for NTLA-2002
- Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema
- ZM, NTLA, or SQ: Which Cathie Wood ARKK Stock Is Most Appealing in 2023?
- Intellia Therapeutics highlights strategic priorities, milestones for 2023